Regenxbio
RGNX
71 hedge funds and large institutions have $236M invested in Regenxbio in 2016 Q3 according to their latest regulatory filings, with 13 funds opening new positions, 28 increasing their positions, 21 reducing their positions, and 10 closing their positions.
60% more capital invested
Capital invested by funds: $147M → $236M (+$89M)
33% more repeat investments, than reductions
Existing positions increased: 28 | Existing positions reduced: 21
30% more first-time investments, than exits
New positions opened: 13 | Existing positions closed: 10
3% more funds holding
Funds holding: 69 → 71 (+2)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$7.62M |
| 2 |
BCPEM
Bain Capital Public Equity Management
Boston,
Massachusetts
|
+$6M |
| 3 |
Axa
Paris,
France
|
+$4.9M |
| 4 |
Millennium Management
New York
|
+$4.54M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$3.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$11.7M |
| 2 |
DM
Deerfield Management
New York
|
-$9.35M |
| 3 |
VMI
VHCP Management II
New York
|
-$7.36M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$4.89M |
| 5 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
-$3.53M |
RGNX Hedge Fund Activity: Q3 2016 in Review
71 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Regenxbio (RGNX) for Q3 2016, worth a combined $236M — up 60% from $147M a quarter earlier.
Buyers outnumbered sellers: 13 funds opened new RGNX positions and 10 closed out — a net gain of 3 holders — while 28 added to existing stakes and 21 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $7.62M. The largest seller was Fidelity Investments, cutting an estimated $11.7M.
- 71 institutional investors held Regenxbio (RGNX) as of Q3 2016, up from 69 in Q2 2016.
- Funds reported $236M of Regenxbio stock for Q3 2016, up 60% quarter-over-quarter.
- 13 funds opened new Regenxbio positions in Q3 2016 and 10 closed out, a net change of +3 holders.
- The largest Regenxbio buyer in Q3 2016 was JP Morgan Chase, an estimated $7.62M added.
- The largest Regenxbio seller in Q3 2016 was Fidelity Investments, an estimated $11.7M sold.
Based on aggregated 13F filings for Q3 2016.